Kee Pharma Eyes 60% Turnover Growth In Fy03

The Delhi-based Kee Pharma targets a 60 per cent growth in turnover in the current financial year after it tied up with two foreign companies to introduce two drugs for cancer and leukoderma. The company, which reported a turnover of Rs 15 crore in the last fiscal year, aims Rs 24 crore by the end of the present fiscal year and Rs 75 crore by 2005-06.

While Interferon Alpha will provide medication on aliments like hepatitis (B and C) and cancer, Melagenina will provide cure for skin disorder Leukoderma, or vitiligo, where the skin develops smooth white patches.

Alok Dev, head, international marketing of Kee Biogenetics, a division of Kee Pharma, said the company has invested heavily in bio-genetics in the past few years and has now introduced the two drugs in Indian market.

 

On Tuesday, Melagenina was introduced in Ahmedabad. Kee Pharma is the sole distributor of the medicine in the country and it is manufactured by Heber Biotech, Cuba.